Melanocyte Cell Culture Portfolio Update

Our Melanocyte Cell Culture Portfolio has been improved with the addition of a new growth medium and melanocytes from juvenile and adult donors. Researchers can now study melanocytes with better growth performance and batch-to-batch standardization.

We have now launched our improved 3rd generation Melanocyte Cell Culture Portfolio featuring:

  • Melanocyte Growth Medium M3: an improved serum-free, bovine pituitary extract (BPE)-free, and phorbol myristate acetate (PMA)-free media formulation; and
  • Normal Human Epidermal Melanocytes M3 from juvenile and adult donors

The newly developed Melanocyte Growth Medium M3 features an improved media formulation which is free of serum, BPE, and PMA. This allows the highest possible degree of standardization when culturing human melanocytes by avoiding commonly used undefined media components such as serum and BPE. Our media also prevents adverse effects on cell metabolism associated with PMA.

Normal human epidermal melanocytes (NHEM) isolated in the Melanocyte Growth Medium M3 are also available from juvenile and adult donors. Additional information regarding tissue localization and pigmentation is available on request for all lots.

Advantages:

  • Complete melanocyte and media portfolio offering guaranteed growth performance
  • BPE-free and serum-free formulation allowing a greater degree of standardization and minimal lot-to-lot fluctuation
  • No adverse effects of PMA on cell metabolism
  • Each produced lot is tested for characteristic cell markers, growth promoting activity and characteristic dendritic cell morphology

 

Choose your Region

Please choose your region for an optimized website experience. So we can provide you with the most useful information for your country.

  1. North America
    1. Canada
    2. United States
  2. Europe
    1. Albania
    2. Austria
    3. Belgium
    4. Bosnia-Herzogovina
    5. Bulgaria
    6. Croatia
    7. Czech Republic
    8. Denmark
    9. Finland
    10. France
    11. Germany
    12. Greece
    13. Hungary
    14. Ireland
    15. Italy
    16. Liechtenstein
    17. Luxembourg
    18. Macedonia
    19. Monaco
    20. Netherlands
    21. Norway
    22. Poland
    23. Portugal
    24. Romania
    25. Serbia
    26. Slovakia
    27. Slovenia
    28. Spain
    29. Sweden
    30. Switzerland
    31. United Kingdom
  3. Asia
    1. Bangladesh
    2. China
    3. Hong Kong (incl. Macau)
    4. India
    5. Indonesia
    6. Israel
    7. Japan
    8. Malaysia
    9. Nepal
    10. Singapore
    11. South Korea
    12. Sri Lanka
    13. Taiwan
    14. Thailand